关键信息
-
基因名
Proinsulin
- 应用
-
别名
INS; Pro-Insulin; Preproinsulin
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 97% as determined by SDS-PAGE.
-
蛋白编号
-
-
表达区间
Phe25~Asn110
-
蛋白长度
Partial
-
分子量
41kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Proinsulin, the precursor of insulin, is a critical component in the regulation of glucose metabolism and is pivotal for the treatment of diabetes. The study of recombinant proinsulin has gained significance due to its potential for therapeutic applications. In the 1920s, insulin was first discovered as a treatment for diabetes, but its production was limited to animal sources until the advent of recombinant DNA technology in the 1970s. This breakthrough allowed for the production of human insulin and proinsulin using genetically modified organisms, such as bacteria and yeast, ensuring a consistent and safer source compared to animal-derived products. Research into proinsulin's structure and function has revealed its role in the formation of insulin, highlighting the importance of understanding this precursor for both basic science and clinical applications. Furthermore, proinsulin itself has generated interest for its potential use as a biomarker for early diabetes detection and as a therapeutic target. Current studies focus on enhancing methods for its production, purification, and characterization, which are essential for ongoing advancements in diabetes management. Investigating proinsulin has thus become a vital area of research, aimed at bridging the gap between basic endocrinology and the clinical treatment of diabetes, ultimately contributing to the development of novel therapies that improve patient outcomes.
